<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646267</url>
  </required_header>
  <id_info>
    <org_study_id>SEL102</org_study_id>
    <nct_id>NCT02646267</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients</brief_title>
  <official_title>The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate the efficacy and safety of dabigatran etexilate
      and different intensity warfarin for the prevention of stroke and systemic embolism in
      patients with non-valvular atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ischaemic stroke</measure>
    <time_frame>2 years</time_frame>
    <description>ischaemic stroke was defined as a blockage in an artery that supplies blood to the brain , resulting in a deficiency in blood flow and focal neurological deficit lasting &gt;24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>major haemorrhage</measure>
    <time_frame>2 years</time_frame>
    <description>Major haemorrhage was defined as intracranial hemorrhage, gastrointestinal bleeding, bleeding requiring hospitalization and surgical intervention, a reduction of hemoglobin by≥2 g/dL, requiring red blood cells transfusion ≥2 units.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>minor bleeding</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary embolism</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>standard intensity warfarin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard intensity warfarin group， target international normalised ratio(INR) was 2.1-3.0, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(2.1-3.0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low intensity warfarin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low intensity warfarin group， target international normalised ratio(INR) was 1.7-2.2, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(1.7-2.2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran etexilate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>110mg dabigatran etexilate was administrated twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard intensity warfarin</intervention_name>
    <description>target international normalised ratio(INR) was 2.1-3.0</description>
    <arm_group_label>standard intensity warfarin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low intensity warfarin</intervention_name>
    <description>target international normalised ratio(INR) was 1.7-2.2</description>
    <arm_group_label>low intensity warfarin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>110mg, twice a day, oral</description>
    <arm_group_label>dabigatran etexilate group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of atrial fibrillation

          2. Echocardiography confirmed a non-valvular heart disease

          3. Age≥60 years

        Exclusion Criteria:

          1. Unable to cooperate with doctors

          2. CHA2DS2-VASc&lt;2

          3. Life expectancy of less than 1 year

          4. Rheumatic heart disease or dilated cardiomyopathy

          5. History of artificial valve replacement surgery

          6. Infectious endocarditis

          7. Stroke or transient ischemic attack(TIA) within the last 6 months

          8. Previous history of intracranial hemorrhage, gastrointestinal, respiratory or
             urogenital bleeding

          9. Previous intolerance/allergy to warfarin or dabigatran etexilate

         10. Blood pressure greater than 180/110 mmHg

         11. Chronic liver dysfunction, alanine aminotransferase above the normal reference value
             of the upper limit 3 times

         12. Chronic renal failure, serum creatinine clearance rate (Ccr) less than 30 ml / min

         13. Patient was receiving antiplatelet or anticoagulant therapy due to other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu Jun, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wu J, Wang J, Jiang S, Xu J, Di Q, Zhou C, Min X, Pang S, Wang H, Xu D, Guo Y. The efficacy and safety of low intensity warfarin therapy in Chinese elderly atrial fibrillation patients with high CHADS2 risk score. Int J Cardiol. 2013 Sep 10;167(6):3067-8. doi: 10.1016/j.ijcard.2012.11.078. Epub 2012 Nov 28.</citation>
    <PMID>23200268</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

